{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:14:16Z","timestamp":1793042056608,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1 R35 NS105109"],"award-info":[{"award-number":["1 R35 NS105109"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["01 P30CA008748"],"award-info":[{"award-number":["01 P30CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001512","name":"National Brain Tumor Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001512","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Non-invasive Characterization of Oligodendroglioma"},{"name":"Agios, and advisory roles with Agios, Puma, NordicNeuroLabs"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lower-grade gliomas (LGGs) with isocitrate dehydrogenase 1 and\/or 2 (IDH1\/2) mutations have long survival times, making evaluation of treatment efficacy difficult. We investigated the volumetric growth rate of IDH mutant gliomas before and after treatment with established glioma therapies to determine whether a significant change in growth rate could be documented and perhaps be used in the future to evaluate treatment response to investigational agents in LGG trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter retrospective study, 230 adult patients with IDH1\/2 mutated LGGs (World Health Organization grade II or III) undergoing surgery, radiation, or chemotherapy for progressive non-enhancing tumor were identified. Subjects were required to have 3 MRI scans containing T2\/fluid attenuated inversion recovery imaging spanning a minimum of 6 months prior to treatment. A mixed-effect model was used to estimate tumor growth prior to treatment. A subset of 95 patients who received chemotherapy, radiotherapy, or chemoradiotherapy and had 2 posttreatment imaging time points available were evaluated for change in pre- and posttreatment volumetric growth rates using a piecewise mixed model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The pretreatment volumetric growth rate across all 230 patients was 27.37%\/180 days (95% CI: [23.36%, 31.51%]). In the 95 patients with both pre- and posttreatment scans available, there was a significant difference in volumetric growth rates before (26.63%\/180 days, 95% CI: [19.31%, 34.40%]) and after treatment (\u221215.24% \/180 days, 95% CI: [\u221221.37%, \u22128.62%]) (P &amp;lt; 0.0001). The growth rates for patient subgroup with 1p\/19q codeletion (N = 118) was significantly slower than the rate of the 1p\/19q non-codeleted group (N = 68) (22.84% vs 35.49%, P = 0.0108).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, we evaluated the growth rates of IDH mutant gliomas before and after standard therapy. Further study is needed to establish whether a change in growth rate is associated with patient survival and its use as a surrogate endpoint in clinical trials for IDH mutant LGGs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaa105","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T15:12:07Z","timestamp":1587395527000},"page":"1822-1830","source":"Crossref","is-referenced-by-count":49,"title":["Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7661-797X","authenticated-orcid":false,"given":"Raymond Y","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M","family":"Ellingson","sequence":"additional","affiliation":[{"name":"UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harini","family":"Veeraraghavan","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Neurology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Tixier","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyemin","family":"Um","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheed","family":"Nawaz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Luks","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Gerstner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[{"name":"Departments of Neurology, Neurological Surgery, and Medicine, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo K","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F","family":"Cloughesy","sequence":"additional","affiliation":[{"name":"Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"2020121802291944900_CIT0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014","volume":"19","author":"Ostrom","year":"2017","journal-title":"Neuro Oncol"},{"issue":"26","key":"2020121802291944900_CIT0002","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"N Engl J Med"},{"issue":"9490","key":"2020121802291944900_CIT0003","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial","volume":"366","author":"van den Bent","year":"2005","journal-title":"Lancet."},{"issue":"4","key":"2020121802291944900_CIT0004","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ana.10528","article-title":"Continuous growth of mean tumor diameter in a subset of grade II gliomas","volume":"53","author":"Mandonnet","year":"2003","journal-title":"Ann Neurol."},{"issue":"1","key":"2020121802291944900_CIT0005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejrad.2008.06.013","article-title":"Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation","volume":"72","author":"Rees","year":"2009","journal-title":"Eur J Radiol."},{"issue":"14","key":"2020121802291944900_CIT0006","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med."},{"issue":"11","key":"2020121802291944900_CIT0007","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol."},{"issue":"6","key":"2020121802291944900_CIT0008","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","article-title":"Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas","volume":"12","author":"van den Bent","year":"2011","journal-title":"Lancet Oncol."},{"issue":"6","key":"2020121802291944900_CIT0009","doi-asserted-by":"crossref","first-page":"W515","DOI":"10.2214\/AJR.09.2615","article-title":"Bidimensional measurements in brain tumors: assessment of interobserver variability","volume":"193","author":"Provenzale","year":"2009","journal-title":"AJR Am J Roentgenol."},{"issue":"3","key":"2020121802291944900_CIT0010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11060-012-0843-2","article-title":"Assessment of intra-observer variability in measurement of high-grade brain tumors","volume":"108","author":"Provenzale","year":"2012","journal-title":"J Neurooncol."},{"issue":"5","key":"2020121802291944900_CIT0011","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0730-725X(95)00012-6","article-title":"Comparison of supervised MRI segmentation methods for tumor volume determination during therapy","volume":"13","author":"Vaidyanathan","year":"1995","journal-title":"Magn Reson Imaging."},{"issue":"3","key":"2020121802291944900_CIT0012","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00330-008-1191-7","article-title":"Reliability of tumor volume estimation from MR images in patients with malignant glioma. Results from the American College of Radiology Imaging Network (ACRIN) 6662 Trial","volume":"19","author":"Ertl-Wagner","year":"2009","journal-title":"Eur Radiol."},{"issue":"2","key":"2020121802291944900_CIT0013","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1148\/radiol.2532081623","article-title":"Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient","volume":"253","author":"Brasil Caseiras","year":"2009","journal-title":"Radiology."},{"key":"2020121802291944900_CIT0014","first-page":"195","article-title":"Simultaneous multi-object segmentation using local robust statistics and contour interaction.","volume-title":"Medical Computer Vision. Recognition Techniques and Applications in Medical Imaging","author":"Gao","year":"2010"},{"key":"2020121802291944900_CIT0015","first-page":"1645","article-title":"Active learning guided interactions for consistent image segmentation with reduced user interactions","volume":"2011","author":"Veeraraghavan","year":"2011","journal-title":"Proc IEEE Int Symp Biomed Imaging."},{"key":"2020121802291944900_CIT0016","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/srep01364","article-title":"GBM volumetry using the 3D Slicer medical image computing platform","volume":"3","author":"Egger","year":"2013","journal-title":"Sci Rep."},{"issue":"4","key":"2020121802291944900_CIT0017","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","article-title":"Random-effects models for longitudinal data","volume":"38","author":"Laird","year":"1982","journal-title":"Biometrics."},{"key":"2020121802291944900_CIT0018","volume-title":"Applied Longitudinal Analysis.","author":"Fitzmaurice","year":"2004"},{"key":"2020121802291944900_CIT0019","volume-title":"Theory of Point Estimation","author":"Lehmann","year":"1998"},{"issue":"1","key":"2020121802291944900_CIT0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-012-0831-6","article-title":"1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth","volume":"108","author":"Goz\u00e9","year":"2012","journal-title":"J Neurooncol."},{"issue":"18","key":"2020121802291944900_CIT0021","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1158\/1078-0432.CCR-12-0084","article-title":"A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy","volume":"18","author":"Ribba","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2020121802291944900_CIT0022","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/neuonc\/noz106","article-title":"Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement","volume":"21","author":"Chang","year":"2019","journal-title":"Neuro Oncol."},{"issue":"5","key":"2020121802291944900_CIT0023","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(19)30098-1","article-title":"Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study","volume":"20","author":"Kickingereder","year":"2019","journal-title":"Lancet Oncol."},{"issue":"9","key":"2020121802291944900_CIT0024","first-page":"1188","article-title":"Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials","volume":"17","author":"Ellingson","year":"2015","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaa105\/33389367\/noaa105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/12\/1822\/34948476\/noaa105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/12\/1822\/34948476\/noaa105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T00:13:19Z","timestamp":1608336799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/22\/12\/1822\/5824395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,4,24]]},"published-print":{"date-parts":[[2020,12,18]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaa105","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,4,24]]}}}